Benefit of delayed fertility therapy with preconception antiandrogenic pretreatment over immediate therapy in polycystic ovary syndrome(PCOS) women with hyperandrogenism

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051638

Enrollment

Unknown

Registered

2021-09-28

Start date

2018-07-01

Completion date

Unknown

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrome

Interventions

experimental group:antiandrogenic pretreatment using ethinylestradiol/ cyproterone acetate (EE/CPA)

control group:Letrozole

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 20-35 years; 2. PCOS was diagnosed according to Rotterdam criteria; 3. women with ovulation disorders and have pregnant plan; 4. Women with clinical or biochemical manifestations of hyperandrogenism, or women with basal LH/FSH >= 1.5; 5. BMI between 18.5 and 26kg/m2.

Exclusion criteria

Exclusion criteria: 1. Women with Hyperprolactinemia or thyroid dysfunction; 2. Type 2 diabetes; 3. Serum FSH > 10 mIU/mL; 4. Male infertility; 5. Diagnosis of fallopian tube abnormalities by HSG or laparoscopy; 6. Endometriosis or pelvic inflammatory disease; 7. Oral contraceptive use or pregnancy contraindications.

Design outcomes

Primary

Measure	Time frame
ovulation rate;	—

Countries

China

Contacts

Public ContactQi Yu

Peking Union Medical College Hospital

yuqi2008001@sina.com+86 13701227034

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026